Greve, Jens http://orcid.org/0000-0003-0628-0608
Kinaciyan, Tamar http://orcid.org/0000-0002-8238-2561
Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Dillenburger, Barbara http://orcid.org/0000-0001-8239-1110
Recke, Andreas http://orcid.org/0000-0002-7674-1804
Schöffl, Clemens
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 25 April 2022
Accepted: 16 May 2022
First Online: 2 September 2022
Conflict of interest
: The contribution of the authors to this article and the editorial support from MWI GmbH were financed by BioCryst Pharma Deutschland GmbH. J. Greve received financial support for research projects from Shire/Takeda and financial allowances for travel expenses and the conference fees for attending a scientific conference from Shire/Takeda and CSL Behring GmbH. T. Kinaciyan received fees for lectures and/or consultancy and/or research funds and support for research, outside of this work, from the following companies: Shire/Takeda, CSL Behring, BioCryst Pharmaceuticals, KalVista and Novartis. M. Maurer is or was until recently a lecturer and/or consultant and/or has received research funds from Alnylam, Astria, BioCryst, Centogene, CSL Behring, Kalvista, Moxie, Pharming, Pharvaris and Shire/Takeda. C. Schöffl received fees and nonfinancial support from Shire/Takeda and CSL Behring and fees from Biocryst and Novartis, outside of this work. B. Dillenburger and A. Recke declare that they have no competing interests.